北京大学医学部生殖健康研究中心于2016年12月由北京大学医学部批准成立，挂靠北京大学第三医院。中心主任为乔杰院士，学术委员会主任为刘以训院士。

         中心定位是成为我国生殖医学领域临床与基础研究中心、生殖健康疾病转化研究平台和人才培养基地。研究方向集成妇产科学、生殖医学、生殖生理学、遗传学、流行病学等学科，具体包括：(1) 女性生育力评估及常见生殖内分泌疾病研究；(2) 胚胎早期发育分子机制与遗传学诊断应用；(3 常见高危妊娠因素的临床研究和干预管理；(4) 妇科恶性肿瘤患者微创手术及生育力保存策略；(5) 围产流行病学队列研究及妇幼健康大数据利用。

        中心依托于北京大学第三医院（北医三院）妇产科建立，合作单位包括北京大学公共卫生学院和北京大学神经科学研究所。北医三院妇产科是国家重点专科，1988年诞生了我国大陆首例试管婴儿，2014年诞生了世界首例利用单细胞扩增基因组测序技术进行胚胎植入前遗传学诊断试管婴儿。目前拥有中国工程院院士1人，教育部长江学者特聘教授1名、国家杰出青年2名、国家自然科学基金委优秀青年2名、中组部青年千人计划1名、北京市优秀人才2名、北京市科技新星2名。中心目前已建设拥有分子遗传诊断中心、医学代谢分析中心、生殖资源标本库、数据管理与分析中心、基础研究实验室、临床干细胞研究中心、生殖内分泌检测平台、单细胞多组学研究平台、转化医学及生殖健康大数据研究平台等。团队先后获得“教育部创新团队”、“国自然基金委创新群体”，获得国家科技进步二等奖2项，教育部高校科技进步一等奖2项，北京市科学技术一等奖、中华医学会科技进步一等奖等奖励10余项。在学科影响力上，北京大学第三医院在“中国医院妇产科领域科技影响力排行榜”中连续四年排名第一；在“中国医院排行榜”中生殖医学学科蝉联专科综合、专科声誉第一名。

        近五年团队获得国家省部级科研基金70余项，累计支持经费近亿元，取得的重要研究成果包括：(1) 建立国内最大的基于社区人群的育龄女性生殖健康监控队列，揭示复杂生殖内分泌疾病发病机制，成功开发女性生殖健康管理系统以及生殖细胞冷冻试剂，并完成成果转化；(2)揭示人类胚胎发育过程细胞分化与器官形成的调控特征及关键分子，创建胚胎植入前遗传学诊断新技术；(3)建立产科危重病协作研究联盟，制定高龄、高危产妇分级管理体系，首次提出胎盘植入超声评分量表用于预测胎盘植入凶险程度；(4)建立常见早期恶性肿瘤年轻患者保留生育功能多学科个体化诊疗模式。以上成果发表SCI论文200余篇，包括Cell、Nature、Science、JAMA、Nature Medicine等；获得专利授予20余项，其中7项成果转化；编写国际国内行业指南4项，专家共识5篇。此外，中心每年举办各类国家级继续教育学习班、国际国内学术研讨会10余次，包括生殖内分泌疾病与辅助生殖技术、疑难母胎疾病诊治与创新手术、妇科恶性肿瘤手术及规范化治疗等，引领生殖医学领域的学科发展，为维护女性生殖健康做出重要贡献。

 

机构负责人：乔杰

联系人：赵越

邮箱：zhaoyue0630@163.com

电话：010-82266590

地址：北京市海淀区花园北路49号

网址链接：http://www.puh3rmc.org/

 

 

Reproductive Health Research Center of Peking University Health Science Center

The establishment of Reproductive Health Research Center was approved by Peking University Health Science Center in December 2016. The director of the center is academician Jie Qiao, and the current director of the academic committee is academician Yixun Liu.

The orientation and construction principles of the center is to become the center of reproductive medicineof China in clinical, the platform of basic research and transformation of reproductive health diseases, and the base of talent training of China reproductive medicine field. Under the leadership of Professor Jie Qiao, the research team has formed three main research directions: (1) evaluation of female fertility and research on reproductive and endocrine diseases; (2) molecular mechanism of early embryonic development and genetic diagnosis; (3) clinical research and intervention management of common high-risk pregnancy factors; (4) minimally invasive surgery and fertility preservation strategies for gynecological cancer patients; (5) cohort study of perinatal epidemiology and big data research on maternal and child health.

The establishment of national clinical research center relies on the department of obstetrics and gynecology of Peking University Third Hospital, which is one of the National key specialties. The two cooperative units include the School of Public Health and the Neuroscience Research Institute, Peking University. The first IVF-ET baby in mainland China was born in Peking University Third Hospital in 1988, and the first born of IVF-ET baby following MALBAC-based whole genome screening in 2014 prove that it has reached the international leading level in the field of assisted reproductive technology research. The research team of key lab currently has an academician of Chinese Academy of Engineering, besides, one person owned the scholar of the Changjiang River, two person owned the National Science Fund for Distinguished Young Scholars, two people owned the National Science Fund for Excellent Young Scholars, one person was enrolled in the Thousand Talents Plan, and four people won the honor of excellent talents of Beijing. By now, a series of platforms has been set up, including the molecular genetic diagnosis center, the medical metabolism analysis Center, the reproductive resources bank, the data management and analysis center, the basic research laboratory, the clinical stem cell research center, the reproductive endocrine detection platform, the single-cell multi omics research platform, and the transformation medicine and reproductive health research platform, etc. The research team has been awarded the "Innovation team of the Ministry of Education", and "National Natural Resources Foundation Innovation Group". We also obtained two second class Prizes for National Scientific and Technology Progress, two first class of the Ministry of Education for Science and Technology Progress, one first class of Beijing Scientific and Technology Progress and more than 10 awards. In terms of subject influence, the Third Hospital of Peking University ranked first for four consecutive years in the ‘technology ranking in the field of gynecology and obstetrics of Chinese hospitals’, and retained the top spot from last year in the ‘ranking in the field of reproductive medicine of Chinese hospitals’ in terms of comprehensive specialty and specialty reputation.

In the past five years, our team have obtained more than 70 scientific research foundations from the country and province, and the total funding was nearly one hundred million RBM. The Important research achievements in recent years were as follows: (1) establishing the largest reproductive health monitoring cohort for reproductive-aged women based on community population in China, revealing the pathogenesis of complex reproductive endocrine diseases, developing the female reproductive health management system and cryopreservation reagent, and completing the transformation of achievements; (2) revealing the regulatory characteristics and key molecules of cell differentiation and organ formation in human embryonic development, and creating a new method of preimplantation genetic diagnosis; (3) establishing the collaborative research alliance of critical obstetric diseases and the hierarchical management system for the elderly and high-risk pregnant women, and putting forward the placental ultrasound score scale for the first time to predict the risk of placental implantation; (4) establishing a multidisciplinary individualized diagnosis and treatment model for fertility preservation in young women with early malignant tumors. Based on the above studies, more than two hundreds SCI publications have been published in Cell, Nature, Science, JAMA, Nature Medicine and other professional journals; more than twenty patents have been granted, severn of which have been transformed; four international and domestic guidelines and five experts consensus have been published. In addition, the center held more than ten national continuing education courses and international and domestic academic seminars every year involving the research fields of reproductive endocrine disease and assisted reproductive technology, diagnosis and treatment of difficult maternal and fetal diseases and innovative surgery, and surgery and standardized treatment of gynecological cancer, etc., leading the development of reproductive medicine in China and making great contributions to the maintenance of female reproductive health.

 

Director: Jie Qiao

Contact: Yue Zhao

Email: zhaoyue0630@163.com

TEL: 010-82266590

Address: No. 49, North Huayuan Road, Haidian District, Beijing

Website: http://www.puh3rmc.org/